A metal-immuno photosensitizer strategy: Iridium(III)-zidovudine conjugate triggering sequential organelle stress and synergizing with PD-L1 inhibitor in oral squamous cell carcinoma

Yiling Li; Peng Wang; Wu-Ya Zhang; Rui Zhou; Jiaying Zhou; Jiawen Chen; Jiayin Wu; Bin Cheng; Cai‐Ping Tan; Tong Wu

doi:10.1016/j.cej.2025.171674

Related Publications

Association of tumor PD-L1 expression and immune biomarkers with clinical activity in patients (pts) with advanced solid tumors treated with nivolumab (anti-PD-1; BMS-936558; ONO-4538).

Joseph F. Grosso , Christine E. Horak , David Inzunza +15 more

3016 Background: The immune checkpoint receptor programmed death-1 (PD-1) negatively regulates T-cell activation. In a phase I study, nivolumab, a PD-1 receptor blocking antibod...

2013 Journal of Clinical Oncology 158 citations

Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer

Takashi Kojima , Manish A. Shah , Kei Muro +24 more

PURPOSE Patients with advanced esophageal cancer have a poor prognosis and limited treatment options after first-line chemotherapy. PATIENTS AND METHODS In this open-label, phas...

2020 Journal of Clinical Oncology 1110 citations

Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti–PD-1 Therapy

Janis M. Taube , Alison Klein , Julie R. Brahmer +7 more

Abstract Purpose: Immunomodulatory drugs differ in mechanism-of-action from directly cytotoxic cancer therapies. Identifying factors predicting clinical response could guide pat...

2014 Clinical Cancer Research 2295 citations

Programmed death ligand 1 expression in hepatocellular carcinoma: Relationship With clinical and pathological features

Julien Caldéraro , Benoı̂t Rousseau , Giuliana Amaddeo +9 more

The prognosis of hepatocellular carcinoma (HCC) remains poor, with only one third of patients eligible for curative treatments and very limited survival benefits with the use of...

2016 Hepatology 430 citations

B7-H1/PD-1 Blockade Therapy in Non–Small Cell Lung Cancer

Scott Gettinger , Roy S. Herbst

Over the past few years, there has been a mounting enthusiasm around the potential of immunotherapy in the treatment of non-small cell lung cancer (NSCLC). This interest was cat...

2014 The Cancer Journal 65 citations

Publication Info

Year: 2025
Type: article
Volume: 527
Pages: 171674-171674
Citations: 0
Access: Closed

External Links

View on DOI.org

Social Impact

Altmetric

A metal-immuno photosensitizer strategy: Iridium(III)-zidovudine conjugate triggering sequential organelle stress and synergizing with PD-L1 inhibitor in oral squamous cell carcinoma

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

OpenAlex

Cite This

APA Style

                            
                                    Yiling Li, 
                                
                                    Peng Wang, 
                                
                                    Wu-Ya Zhang
                                
                                et al.
                            
                            (2025). 
                            A metal-immuno photosensitizer strategy: Iridium(III)-zidovudine conjugate triggering sequential organelle stress and synergizing with PD-L1 inhibitor in oral squamous cell carcinoma. 
                            Chemical Engineering Journal
                            , 527
                            
                            , 171674-171674.
                            https://doi.org/10.1016/j.cej.2025.171674

Identifiers

DOI: 10.1016/j.cej.2025.171674